Literature DB >> 20226877

Alterations of cholesterol precursor levels in Alzheimer's disease.

Heike Kölsch1, Reinhard Heun, Frank Jessen, Julius Popp, Frank Hentschel, Wolfgang Maier, Dieter Lütjohann.   

Abstract

Cerebral and extracerebral cholesterol metabolism are altered in Alzheimer's disease (AD) as indicated by reduced plasma levels of the cholesterol elimination products 24S-hydroxycholesterol, which is of cerebral origin, and of 27-hydroxycholesterol, which is formed extracerebrally. However, it has to be evaluated, if changes of cholesterol metabolism in the whole body or in the CNS are exclusively due to the altered elimination of cholesterol or are also due to altered de novo synthesis in AD. We investigated CSF and plasma levels of cholesterol and of its precursors lanosterol, lathosterol and desmosterol in AD patients and non-demented controls. We found CSF levels of cholesterol (p=0.011), absolute levels of all investigated cholesterol precursors (each p<0.001) and ratios of cholesterol precursors/cholesterol (each <0.01) to be lower in AD patients as compared to controls. In plasma, the absolute levels of lanosterol (p=0.026) and lathosterol (p<0.001) and the ratio of lathosterol/cholesterol (p=0.002) but none of the other investigated parameters were reduced in AD patients (p>0.1). Furthermore, ratios of desmosterol/lathosterol in CSF (p=0.023) and plasma (p=0.009) were higher in AD patients as compared to controls. Our data support the hypothesis that cholesterol metabolism is altered in AD and further suggest that especially cholesterol de novo synthesis within the CNS of AD patients might be reduced. These findings raise doubt on a beneficial effect of cholesterol lowering treatment in manifest AD. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20226877     DOI: 10.1016/j.bbalip.2010.03.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  17 in total

Review 1.  Cholesterol, 24-Hydroxycholesterol, and 27-Hydroxycholesterol as Surrogate Biomarkers in Cerebrospinal Fluid in Mild Cognitive Impairment and Alzheimer's Disease: A Meta-Analysis.

Authors:  Hua-Long Wang; Yan-Yong Wang; Xin-Gang Liu; Sheng-Han Kuo; Na Liu; Qiao-Yun Song; Ming-Wei Wang
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

2.  Nanostructure-initiator mass spectrometry (NIMS) imaging of brain cholesterol metabolites in Smith-Lemli-Opitz syndrome.

Authors:  G J Patti; L P Shriver; C A Wassif; H K Woo; W Uritboonthai; J Apon; M Manchester; F D Porter; G Siuzdak
Journal:  Neuroscience       Date:  2010-07-27       Impact factor: 3.590

Review 3.  Insulin resistance and impaired lipid metabolism as a potential link between diabetes and Alzheimer's disease.

Authors:  Joshua A Kulas; Thaddeus K Weigel; Heather A Ferris
Journal:  Drug Dev Res       Date:  2020-02-05       Impact factor: 4.360

4.  Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology.

Authors:  Yoshiaki Sato; Ikumi Suzuki; Tatsuji Nakamura; Francois Bernier; Ken Aoshima; Yoshiya Oda
Journal:  J Lipid Res       Date:  2011-12-27       Impact factor: 5.922

Review 5.  Recent advances in the application of metabolomics to Alzheimer's Disease.

Authors:  Eugenia Trushina; Michelle M Mielke
Journal:  Biochim Biophys Acta       Date:  2013-06-29

6.  Identification and characterization of prescription drugs that change levels of 7-dehydrocholesterol and desmosterol.

Authors:  Phillip A Wages; Hye-Young H Kim; Zeljka Korade; Ned A Porter
Journal:  J Lipid Res       Date:  2018-08-07       Impact factor: 5.922

Review 7.  Cholesterol in brain disease: sometimes determinant and frequently implicated.

Authors:  Mauricio G Martín; Frank Pfrieger; Carlos G Dotti
Journal:  EMBO Rep       Date:  2014-09-15       Impact factor: 8.807

8.  Lanosterol induces mitochondrial uncoupling and protects dopaminergic neurons from cell death in a model for Parkinson's disease.

Authors:  L Lim; V Jackson-Lewis; L C Wong; G H Shui; A X H Goh; S Kesavapany; A M Jenner; M Fivaz; S Przedborski; M R Wenk
Journal:  Cell Death Differ       Date:  2011-08-05       Impact factor: 15.828

9.  Lipid rafts and Alzheimer's disease: protein-lipid interactions and perturbation of signaling.

Authors:  David A Hicks; Natalia N Nalivaeva; Anthony J Turner
Journal:  Front Physiol       Date:  2012-06-22       Impact factor: 4.566

10.  Evaluating a targeted multiple reaction monitoring approach to global untargeted lipidomic analyses of human plasma.

Authors:  Mostafa J Khan; Simona G Codreanu; Sandeep Goyal; Phillip A Wages; Santosh K K Gorti; Mackenzie J Pearson; Isabel Uribe; Stacy D Sherrod; John A McLean; Ned A Porter; Renã A S Robinson
Journal:  Rapid Commun Mass Spectrom       Date:  2020-11-30       Impact factor: 2.586

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.